Goldman Sachs Downgrades ImClone (IMCL) to Neutral
More News related to BMY
- Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor
- Bristol-Myers Squibb to Present at Healthcare Conference
- Tekmira Pharmaceuticals Corporation Announces Third Quarter 2008 Operating Results and Provides Program Update
- Athersys Announces Clinical Development Milestone in Bristol-Myers Squibb Discovery Alliance
- Notable Analyst Rating Changes 11/07: ANF, TWTC, CECEO Upgraded; TM, DLB, SI Downgraded
More News related to IMCL
- NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum
- Lilly Completes Cash Tender Offer for ImClone Systems
- ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
- Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
More News related to Downgrades
- After-Hours Movers 12/01: Palm (PALM), Mosaic (MOS) Lower on Guidance
- Trading Radar for 12/02: Staples (SPLS), Marvell (MRVL), Solarfun (SOLF), Beazer (BZH), Sears (SHLD) Report; Auto/Truck Sales for Nov. Due
- Unusual 11 Mid-Day Movers 12/01: MNT, PSUN, ALD, PGI Higher; PPC, MTL, EXM, LIZ Lower
- Notable Analyst Rating Changes 12/01: PRU, TOL, DO, WLP Upgraded; SNP, LTD, COG, ADM Downgraded
- Notable Mergers and Acquisitions of the Day 12/01: JNJ/MNT, AIG, F, FFH
Goldman Sachs downgrades ImClone (Nasdaq: IMCL) from Buy to Neutral with a $64 price target, citing valuation.
NOTE: There is currently at $60/share bid for ImClone on the table from partner Bristol-Myers (NYSE: BMY).
ImClone Systems Incorporated, a biopharmaceutical company, engages in the development and commercialization of a portfolio of targeted treatments for the medical needs of patients with cancer in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
-1.34
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
